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Objectives: Although prior research has shown that self-efficacy (SE), the belief that one has the 
ability to create change through behaviors, is associated with better clinical outcomes for Type 2 
diabetes (DM) and coronary artery disease separately (CAD), little research has examined the 
role of SE in patients with both DM and CAD. The goal of this cross-sectional analysis was to 
describe the association between SE and glycosylated hemoglobin (HbA1c), systolic blood 
pressure (SBP), and low density lipids (LDL) in patients with comorbid CAD and DM. In 
addition, this analysis examined the demographic and clinical factors that are associated with SE 
in the management of DM and CAD. 
Methods: Bivariate and multivariate analyses were conducted with 1,447 patients in the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) study who completed a self-
efficacy assessment. Only patients recruited at U.S. sites were included in the analyses. The 
majority of the patients were White non-Hispanic, male, and had a post high school education. 
The average age at enrollment was 63 years. The models were adjusted for sex, age, 
race/ethnicity, and education. 
Results: Better HbA1c was positively associated with SE, even after adjusting for race/ethnicity, 
age, sex, and education. Better SBP was positively associated with SE, however this association  
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was only marginally significant when adjusting for race/ethnicity, age, sex, and education. LDL 
was not associated with SE. Hispanic ethnicity, history of congestive heart failure, number of 
hypertension drugs, probable neuropathy, and insulin use were factors negatively associated with 
SE. A post high school education and history of cancer were positively associated with SE.  
Conclusions: Psychosocial factors, such as self-efficacy, are of public health significance 
because they play a considerable role in the management of diabetes and cardiovascular disease. 
Self-efficacy was positively associated with better cardiac and diabetic factors in the BARI 2D 
population. Literacy skills, cardiac history, number of medications, and neuropathy are several 
other factors doctors should take into consideration when assessing and building up patients’ 
confidence in being able to manage their medical conditions.  
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1.0  INTRODUCTION 
A large number of Americans suffer from preventable and treatable diseases, two of 
which are Type 2 diabetes mellitus (DM) and coronary artery disease (CAD).  DM 
accounts for 90 – 95% of the 15.8 million diabetes cases diagnosed in the United States 
(CDC, 2005). Additionally, CAD is the leading cause of death in the U.S., with more 
than a half million people dying from CAD annually (NHLBI, 2007).  In order to treat 
these diseases, patients with both DM and CAD must engage in daily treatment regimens 
to regulate blood glucose levels and balance diet and exercise. These regimens can 
include, but are not limited to, monitoring of blood glucose with a blood glucose monitor, 
complex drug regimens including oral hypoglycemic drugs as well as lipid and blood 
pressure drugs, use of insulin, proper care of feet, dieting, and exercise. These steps are 
essential for health maintenance and the management of these chronic diseases 
(Anderson, Funnell, Fitzgerald, & Marrero, 2000). 
 Several studies have documented the difficulty of DM management even under 
the care of the best physician (Jerant, Friederichs-Fitzwater, & Moore, 2005; Nelson, 
McFarland, & Reiber, 2007). The patient’s motivation, ability, and social support needed 
to adhere to medication and lifestyle regimens are key in controlling the diseases and 
reducing the risk of complications of DM, including CAD. One must also consider how 
well the person believes they are able to carry out the steps needed to keep their DM and 
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cardiovascular disease under control. Research defines this belief as self-efficacy (SE) 
and many studies have documented the significance of SE in reducing an individual’s 
risk for adverse health outcomes and morbidities (Bandura, 1977; Chlebowy & Garvin, 
2006).   
 According to findings from the Bypass Angioplasty Revascularization 
Investigation (BARI) study, patients with DM had a significantly higher incidence of 
morbidities and mortality after cardiovascular revascularization compared to patients 
without diabetes (BARI_Investigators, 1997). This led to the proposal of the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) study, which 
investigates the effect of glycemic control and cardiovascular intervention in patients 
with DM and mild to moderate CAD (Brooks et al., 2006). Using baseline data from the 
BARI 2D study, the primary aims of the current analyses are to 1) describe the 
association between SE and risk factor control; and 2) identify the factors that are 
associated with SE in the management of DM and CAD in BARI 2D patients. It is 
hypothesized that SE will be positively associated with glycemic control, blood pressure, 
and lipids. In addition, it is hypothesized that after controlling for sex, age, race/ethnicity, 
and education, both cardiovascular and diabetic clinical factors will be associated with 
SE. Results of this analysis may provide a better understanding of the relationships 
among clinical, demographic, and psychosocial factors shaping health outcomes.  The 
results may help healthcare professionals incorporate SE motivational methods into 
treatment, management, and patient education materials designed for patients with DM 
and CAD. 
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1.1 LITERATURE REVIEW 
The objective of this literature review is to identify studies focused on SE as a 
psychosocial factor in populations with the co-morbid conditions of DM and CAD. A 
search for articles related to this topic was undertaken to include both historical and 
current research.  This was supplemented by additional searches of article reference lists 
and scans of cardiovascular, diabetes, and psychiatric journals.  The search for 
appropriate articles was undertaken using the MEDLINE database through the PubMed 
and Ovid search engines with keywords: cardiovascular, coronary, Type 2 diabetes, self-
efficacy, and self-management.  Search results were limited to English publications, full 
text (Ovid only) and adult samples (age 19 and over; PubMed only). There were no 
specifications for the years in which the articles were published. The first part of the 
literature review describes Bandura’s theory of SE (1977) and its implications for health 
management, followed by an exploration of SE in relation to DM and CAD management.  
Studies selected by their specific focus on SE and DM/CAD will be described in terms of 
the operational definition of SE, effect size, study design, diversity of study population, 
and research methods.   
1.2 SELF-EFFICACY: ORIGINS AND MEASUREMENT 
The concept of “readiness to change” was coined by Bandura (1977) as one construct in 
his social cognitive theory of human behavior.  Over time, consensus emerged around the 
term “self-efficacy” to define a person’s confidence in being able to make change 
(Bandura, 1977, 1982). Within the concept of SE, mastery of a required skill gives one 
confidence to continue to utilize this skill. SE arises from 1) performance 
accomplishments (how well they have controlled their DM and CAD), 2) vicarious 
experience (fellow patients’ experiences in self-management), 3) verbal persuasion 
(medical advice), and 4) physiological states (emotional arousal in coping with 
threatening situations) (Bandura, 1977, 1982). SE differs from outcome expectancies in 
that it focuses on the belief in one’s skills in performing an act, rather than the outcome 
of the act itself (Figure 1) (Bandura, 1977, 1982). A person can believe that an act will 
produce a desired outcome, but if s/he does not believe the act can be mastered, then the 
behavior will not be executed. 
 
PERSON BEHAVIOR OUTCOME 
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Figure 1. Bandura’s conceptual model of self-efficacy (Bandura, 1997) 
 
Expectations of SE determine whether or not the self-management behaviors will 
commence, how long they will be done, and whether or not they will persist during 
obstacles and difficult circumstances (Bandura, 1977, 1982). This is of importance to the 
medical field because one’s belief that s/he is able to effectively manage his/her health 
mediates change, and these beliefs are readily stimulated and formed by one’s successes 
with self-management of his/her diseases (Anderson et al., 2000; Bandura, 1977). More 
Efficacy Expectations 
- Performance accomplishments 
- Vicarious experience 
- Verbal persuasion 
- Emotional arousal 
Outcome Expectations 
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often than not, patients perceive barriers to active self-management of chronic conditions. 
Depression, difficulty exercising, poor communication with healthcare professionals, low 
family support, physical pain, and financial problems are the most commonly noted 
barriers (Jerant et al., 2005). Furthermore, the lack of drive to fully engage in the 
regimens related to chronic conditions can result in poor outcomes and additional 
utilization of the medical system (Jerant et al., 2005). The relationship between drive and 
outcomes is consistent among age groups, literacy levels, and races (Nakahara et al., 
2006; Sarkar, Fisher, & Schillinger, 2006). 
Bandura’s model was the theoretical context for development of the Chronic 
Disease Self Management Program launched by researchers at Stanford University 
(Lorig, 1996). They realized that the effectiveness of chronic disease management is 
highly contingent on the self-care behaviors of the patients. This program has been shown 
to improve SE, self-management behaviors, and health outcomes, as well as reduce 
hospitalizations. Therefore, it is important to understand the interaction between chronic 
conditions such as DM and CAD and the patients’ self-management behaviors in order to 
improve their health outcomes (Deaton et al., 2006). Part of the program included the 
development of a global assessment tool that could measure SE in patients. 
Assessment of SE can be either global or disease-specific. Global assessments 
such as the one by Lorig (1996) can be altered and used in multiple fields such as disease 
management, education, or webpage development. However, disease-specific 
assessments, such as the Cardiac Self-Efficacy Scale and Diabetes-Related Self-Efficacy 
assessment from the Multidimensional Diabetes Questionnaire, utilize questions that 
target specific self-management behaviors based on the disease. 
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Although many studies have used different SE assessments, it is often shown that 
SE is positively associated with one’s cardiac and diabetic health status and management 
in studies that have investigated the diagnoses separately (Nakahara et al., 2006; Sarkar et 
al., 2006; Sol, van der Graaf, van der Bijl, Goessens, & Visseren, 2006). Numerous 
published studies have investigated the role of SE as a factor in DM or CAD, but these 
studies have been limited by focusing on one disease.  Far fewer studies have 
investigated the role of SE in patients with both DM and CAD, a population at increased 
risk of premature morbidity and mortality. Therefore, more research is needed to 
disentangle the risk factors associated with the co-morbidities of DM and CAD.   
1.3 TYPE 2 DIABETES MELLITUS 
A total of 88 articles in PubMed and 74 articles in Ovid were identified that focused on 
DM and SE. DM is a condition in which the body either does not produce enough insulin 
or becomes insulin resistant. It begins with the body’s resistance to insulin production. As 
a result, the pancreas over-secretes insulin to the point at which it can no longer 
effectively produce enough. Complications resulting from DM include neuropathy, CAD, 
hypertension, renal disease, and amputation of the limbs (Chlebowy & Garvin, 2006).  In 
order to keep DM under control, patients must make a number of daily decisions 
regarding medication, glucose monitoring, nutrition, physical activity, and stress 
management (Anderson et al., 2000). DM self-management is strongly related to disease 
control and outcomes (Franz et al., 2002). However, the literature presents evidence of 
mixed results regarding the relationship between glycemic control and SE with some 
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studies documenting no association and others showing a strong association. This may be 
due to the types of SE assessments used. 
A study by Chlebowy and Garvin (2006) utilized a two-group comparative 
descriptive design to examine the relationships between social support, SE, and outcome 
expectations to DM self-care behaviors and glycemic control in Caucasian and African 
American participants (N=91). Instruments used were the Social Support Questionnaire, 
Self Efficacy Questionnaire (SEQ), Outcome Expectancy Questionnaire, and the 
Diabetes Activities Questionnaire. All scales were found to be highly reliable including 
the SEQ (α coefficient for overall score=0.92). SE was not significantly related to 
glycemic control for either race, while outcome expectation was significantly related to 
glycemic control.  
In a one-year prospective study, Nakahara et al. (2006) examined the causal 
relationship between psychosocial factors and DM in 256 Japanese men. SE was 
measured by the Diabetes-Related Self-Efficacy section of the Multidimensional 
Diabetes Questionnaire, which has high internal consistency (Crohnbach’s α=0.80).  This 
is a 0-100 Likert scale ranging from “0=not at all” to “100=very.” Additional instruments 
used were the Problem Areas in Diabetes, Life and Health Related Questionnaires, and 
Profile of Mood States. SE was significantly related to good regimen adherence (r=0.56, 
p<0.01), and adherence had a direct association with glycosylated hemoglobin A1c 
(HbA1c) over time. HbA1c six months post-baseline was both directly and indirectly 
associated with adherence, SE, social support, daily burden, DM-related distress, and 
emotion-focused coping. 
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Sarkar et al. (2006) examined the relationship between SE and DM management 
in a racially diverse, low-income population with limited ability to read and comprehend 
written health materials (health literacy). Patients (N=408) with DM were given an oral 
questionnaire in either English or Spanish. SE was measured with a 4-point Likert scale 
from “1=not sure at all” to “4=very sure.” SE was significantly associated with diet, 
exercise, self-monitoring of blood glucose, and foot care, even after controlling for DM 
factors, race, and health literacy. Medication adherence was not significantly associated 
with SE (OR=1.04, 95% CI=0.93-1.17), but a self-report may not be the best measure for 
assessing medication adherence as patients are prone to recall bias. 
A study by Nelson et al. (2007) assessed factors associated with the self-
management of DM among veterans with poor glycemic control (HbA1c≥8.0%). Surveys 
were mailed to patients of the Washington State Veteran Affairs Medical Centers, 
yielding a 57% response rate (N=717). The surveys contained assessments of SE, 
readiness to change, physician’s advice, and DM self-management. SE was assessed 
using the 4-item Perceived Competence in Diabetes Scale (Crohnbach’s α ≈ 0.80 – 0.94), 
which accounts for the stages of change (Bandura, 1977). They noted that individuals 
with higher SE scores were more likely to follow their medication therapy, maintain 
proper nutrition, adhere to a blood glucose-monitoring schedule, and be physically active 
(p<.001). The data collected were self-reported so it may be limited by recall bias and 
non-response bias. 
There are several issues one must consider with SE and DM research. One, 
although different assessments of SE were used in each study, results consistently 
showed that SE was positively associated with behaviors related to DM management.  
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Whether or not HbA1c is related to SE is still to be determined. Two, DM management 
may be based on the participant’s exposure to DM education. Patients with DM education 
may be more likely to perform the needed daily tasks regarding health maintenance and 
they may also be of high socioeconomic status, thereby having a more positive DM 
profile (Chlebowy & Garvin, 2006). Furthermore, DM has high comorbidty with 
depression (10-15%), which has been shown to affect SE, adherence to self-care 
regimens, and quality of health (Ciechanowski, Katon, & Russo, 2000; Katon et al., 
2004). Some of the symptoms of major depression are lack of interest, psychomotor 
agitation, and fatigue which may result in people with DM and depression being less 
motivated to exercise, adhere to their diet, and take their medications (DSM-IV-
TR_American_Psychiatric_Association, 2000). Additionally, few studies reported their 
patient’s cardiac status. Patients with a comorbid cardiac condition have poorer SE than 
those without (Deaton et al., 2006). 
1.4 CORONARY ARTERY DISEASE 
A total of 211 articles in PubMed and 147 articles in Ovid were found relating to CAD 
and SE. CAD occurs when the coronary arteries become hardened and narrowed due to 
atherosclerosis. Blood flow to the heart muscle is reduced, resulting in angina, 
myocardial infarction (MI), cardiac arrest, or arrhythmias.  CAD is also one of the main 
causes of activity limitations, besides arthritis (Sullivan, LaCroix, Russo, & Katon, 
1998). Although the studies have shown a relationship between CAD and functional 
capacity as measured by the Duke Activity Status Index (DASI) and the Medical 
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Outcomes Study 36-Item Short Form (SF-36), SE has been shown to be related to 
behaviors that affect CAD prevention and outcomes (Sullivan et al., 1996). SE has been 
shown to predict adherence to exercise and dietary regimens (Robertson & Keller, 1992; 
Sullivan et al., 1998). 
A study by Sullivan et al. (1998) prospectively examined the role of SE in 
patients with CAD (N=198), controlling for anxiety and depression. Like the BARI 2D 
study (Brooks et al., 2006), patients were eligible for elective surgery. Instruments used 
were the 13-item Cardiac Self-Efficacy Scale, which looked at function maintenance and 
symptom control, the SF-36 (physical functioning), and the Sheehan Family/Home and 
Social Interference Scales (disability). CAD was measured by the number of coronary 
vessels with >70% stenosis, because it showed the strongest relation to self-reported 
physical function compared to any other angiographic measure in their past studies on the 
same cohort (as cited by Sullivan et al., 1998). The effect of left main stenosis, a measure 
of CAD severity, on SE was not found to differ from the effect of stenosis of the other 
principal arteries. Patients with ST segment depression (cardiac ischemia) were also 
found to have better self–reported function than those with less ST segment depression. 
SE was found to be a good predictor of physical function and role function after 
controlling for CAD severity, anxiety, and depression.  This study is limited in that the 
validity of the SE assessment scale that was used is still to be determined. 
The goal of a study by Sarkar et al. (2007) was to examine the relationship 
between cardiac SE and health status in 1,024 patients with congestive heart disease in 
the Heart and Soul Study, controlling for severity of congestive heart disease and 
depression. Cardiac SE was measured using Sullivan’s 5-item scale (Crohnbach’s α = 
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0.80) (Sullivan et al., 1998). Lower SE was found to be independently associated with 
greater cardiac symptom burden, greater physical limitations, worse quality of life, and 
worse overall health. Since the study is cross-sectional, directionality and causality 
cannot be established. Furthermore, the majority of the patients were older, low-income 
White males, limiting the generalizability of the results. 
In a longitudinal study of a Turkish cohort, 60 cardiac patients were randomized 
to a home-based cardiac exercise program (HBCEP) or no intervention (control) in order 
to study each group’s lipids, exercise tolerance, and SE (Senuzun, Fadiloglu, Burke, & 
Payzin, 2006).  Grounded in the theory of SE, the HBCEP included exercise information 
(vicarious experience) and regular counseling sessions over the telephone, which were 
meant to monitor the patients’ exercise diaries (performance accomplishments), provide 
physiological feedback (physiological states), and boost SE through social persuasion 
(verbal persuasion). Blood samples were collected pre-entry and 12 weeks later to 
measure the 12-hour fasting lipid profiles. SE was measured by the Cardiac Self-Efficacy 
Index (CESEI), whose test-retest reliability was 0.97 (Crohnbach’s α=0.87). At the end of 
the 12 weeks, the HBCEP group significantly improved in comparison to the control 
group in total cholesterol (p=0.004), low density lipid cholesterol (LDL; p=0.04), high 
density lipid cholesterol (HDL; p<.001), systolic blood pressure (p=0.04), diastolic blood 
pressure (p=0.04), and SE (p<.001). Senuzun et al. (2006) concluded that exercise along 
with SE might have improved the patients’ exercise capacity, thereby improving their 
clinical outcomes. However, this conclusion may be premature in that the control group 
did not receive any intervention. An additional control group that would warrant such a 
 12 
conclusion would be composed of patients who received an exercise program that was 
not grounded in the SE theory. 
There are several issues that previous research findings raise for future 
investigation into CAD and SE.  There are multiple measures of CAD that overlap. For 
instance, CAD can be measured by either extent (number of lesions with ≥50% stenosis) 
or severity (Myocardial Jeopardy Index). Furthermore, since both exercise and 
medications have been found to improve the status of several variables such as lipid 
values and blood pressure, special care must be taken to disentangle the interaction 
between drugs and medications on these variables. 
1.5 DIABETES AND CARDIOVASCULAR DISEASE COMORBIDITY 
A total of 22 articles in PubMed and 5 articles in Ovid were found relating to CAD, DM, 
and SE. CAD is a major complication in patients with DM, resulting in an increased risk 
of morbidity and mortality compared to patients with CAD alone (Deaton et al., 2006). 
The risk of CAD-related complications in those with DM is two to four times greater 
compared to those without DM (Stamler, Vaccaro, Neaton, & Wentworth, 1993). Patients 
with DM and CAD experience far worse clinical outcomes than patients with no DM as a 
result of CAD events and cardiac revascularization attempts (Sobel, Frye, & Detre, 
2003). In fact, approximately 75% of most White populations with DM will die of 
cardiovascular disease (Laasko & Lehto, 1997). To date, there is limited research on SE 
in patients with both DM and CAD. The following article by Deaton et al. (2006) was 
chosen for review based on its specific focus on SE and DM/CAD.  Most of the articles 
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found in the literature search did not look at this topic in depth and they referenced the 
Deaton article. 
Deaton et al. (2006) studied symptom distress, self-management, and general and 
cardiac health status in 1,013 congestive heart disease patients with and without DM in 
the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial 
(COURAGE). Self-management was measured by the Self-Management Difficulties 
Scale, which was adapted from a similar tool used to measure diabetic self-management 
(Crohnbach’s α=0.89). Researchers found the effects of both diseases to be synergistic. 
Patients with DM and a greater severity of DM had more self-management difficulty 
regarding medication, exercise, and diet (DM severity only). They also had more physical 
limitations that promoted the difficulties in self-management. Congestive heart disease 
was the most important comorbid factor in explaining a poorer risk factor profile for 
disability in patients with DM. DM was independently associated with increased odds of 
disability in this patient population. Variables found to be associated with self-
management were age, angina status, severity of DM, renal disease, symptom distress, 
and social support (R2=0.12, p=0.03). This study was limited in that it was cross-sectional 
and used mainly White male patients. However, it is similar to BARI 2D in that it was 
composed of patients with congestive heart disease suitable for revascularization. 
Thus, the limited literature has shown that both the management and outcomes of 
DM and CAD in terms of adherence to medications, exercise, glucose monitoring, ST 
segment depression, lipids, blood pressure, and foot care are highly related to SE.  Future 
research must be done on a more demographically diverse population, because racial 
minorities such as Blacks and Native Americans are disproportionately affected by DM 
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and CAD (AHA_ASA, 2007; CDC, 2005). Future research on the association between 
SE and DM/CAD management is needed.  
The current analysis will examine 1) how SE is related to the following DM and 
CAD risk factor outcome measures: HbA1c, LDL, and systolic blood pressure, and 2) 
examine which clinical factors are related to SE in a diverse cohort of patients with both 
DM and CAD. It is hypothesized that SE will be positively associated with better HbA1c, 
LDL, and systolic blood pressure, and that both DM and CAD variables will be 
associated with SE. 
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2.0  METHODS 
2.1 STUDY DESIGN 
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) study is 
a National Institutes of Health (NIH) sponsored randomized clinical trial designed to 
examine optimal treatment strategies for patients with DM and documented stable CAD 
(Brooks et al., 2006).  This study has 49 clinical sites in the United States, Brazil, 
Canada, Mexico, the Czech Republic, and Austria, and the Coordinating Center is located 
at the University of Pittsburgh Graduate School of Public Health (Pittsburgh, PA). Using 
a 2x2 factorial design (Table 1), BARI 2D patients are randomized to immediate elective 
revascularization combined with aggressive medical therapy versus initial aggressive 
medical therapy alone, and to an insulin-providing versus an insulin-sensitizing strategy 
of glycemic control (target HbA1c <7.0% for all patients). BARI 2D is an on-going IRB 
approved study. This secondary data analysis has been approved by the University of 
Pittsburgh IRB (IRB# PRO07090264). 
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Table 1. BARI 2D study design by randomized treatment assignment 
Revascularization  Strategy 
Percentage of Patients Per Treatment Assignment 
Revascularization Medical Management 
Insulin-Providing 579 585 
Glycemic Control Strategy 
Insulin-Sensitizing 568 589 
 
Randomization is stratified by BARI 2D site and by intended revascularization -- 
either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).  
Patients who are randomized to immediate revascularization receive surgery by a BARI 
2D certified technician within four weeks of randomization. Patients randomized to initial 
aggressive medical therapy may receive revascularization at a later stage in the trial, in 
the event of worsening symptoms or a cardiac event. All patients receive aggressive 
medical therapy for health complications associated with DM and CAD, such as 
dyslipidemia, hypertension, and angina, based on the BARI 2D protocol.  The protocol 
also includes a non-pharmacologic Lifestyle Program aimed at smoking cessation, weight 
loss, foot care, and proper exercise.  
Randomization to either insulin-sensitizing drugs or insulin-providing drugs 
requires that patients adopt the assigned form of drug therapy, regardless of their prior 
form of therapy. If over the course of the study, a patient’s HbA1c remains >8.0%, s/he is 
mandated to receive glucose-lowering drugs from the other arm. Additional control of 
HbA1c is based on an algorithm for optimal glycemic control through combination 
therapy (Magee & Isley, 2006). 
Recruitment began January 1, 2001 and ended March 31, 2005. At the baseline 
visit, extensive clinical, demographic, and psychosocial data are collected including 
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education, employment status, body mass index (BMI), HbA1c, duration of DM, history 
of MI, blood pressure, lipid values, and number of medications. Study participants also 
complete a comprehensive battery of self-reported psychosocial measurements including 
four questions regarding SE. 
Follow-up visits occur monthly for the first six months and quarterly thereafter, 
until the end of the study in 2008. At each follow-up visit, information about clinical risk 
factors, diabetes complications, clinical events, and medications is collected.  The 
projected mean follow-up per patient is 5.2 years. The BARI 2D primary endpoint is all-
cause mortality. The composite secondary endpoint is death, stroke, or MI (heart attack). 
Although this is a prospective longitudinal study, only cross-sectional data at study entry 
were available at the time of this analysis. 
2.2 SUBJECTS  
BARI 2D participants were enrolled from clinical sites in the United States, Canada, 
Brazil, Mexico, the Czech Republic, and Austria (N=2,368). Eligible patients have a 
“diagnosis of DM and angiographically documented CAD for which revascularization 
was not required for prompt control of severe or unstable angina” (Brooks et al., 2006, p. 
10G).  A physician/investigator at each site determined if the patients were eligible for 
the study based on inclusion/exclusion criteria. Based on the BARI 2D Manual of 
Operations (BARI_2D_Coordinating_Center, 2002-2005), inclusion criteria were as 
follows: diagnosis of Type 2 diabetes mellitus, coronary arteriogram showing one or 
more vessels amenable to revascularization (≥50% stenosis), objective documentation of 
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ischemia or subjectively documented typical angina with ≥70% stenosis in at least one 
artery, suitability for coronary revascularization by at least one of the available methods, 
ability to perform all tasks related to glycemic control and risk factor management, age 
25 or older, and informed written consent (Brooks et al., 2006). Exclusion criteria were as 
follows: definite need for invasive intervention as determined by a cardiologist, any prior 
CABG (bypass surgery) within the past twelve months, prior PCI (stent placement) 
within the past 12 months, class III or IV congestive heart failure, creatinine > 2.0 mg/dl., 
HbA1c > 13%, need for major vascular surgery concomitant with revascularization (e.g., 
carotid endarterectomy), left main stenosis > 50%, non-cardiac illness limiting mortality, 
hepatic disease, fasting triglycerides > 1000 mg/dl in the presence of moderate glycemic 
control (HbA1c <9.0%), current alcohol abuse, chronic steroid use, 
known/planned/suspected pregnancy, geographically inaccessible or unable to return for 
follow-up, enrolled in a competing randomized trial or clinical study, and unable to 
understand or cooperate with protocol requirements (Brooks et al., 2006). 
 The recruitment pattern for patients differed according to site. Patients were 
generally recruited through screenings conducted in the cardiac catheterization 
laboratory, stress test laboratory, and outpatient clinics both inside and outside of the 
study site. Since DM and CAD affect racial/ethnic minorities disproportionately 
(AHA_ASA, 2007; CDC, 2005), there was a strong aim to recruit at least 30% minority 
participants. A minority recruitment and retention committee was established at the BARI 
2D Coordinating Center to provide technical assistance. Before randomization, it is 
required that all patients give signed informed consent which also contained Health 
Insurance Portability and Accountability Act (HIPAA) information.  
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Of the 2,368 randomized BARI 2D patients, 2,321 had <20% missing baseline 
data and these patients form the BARI 2D baseline population used for cross-sectional 
correlation analyses. Due to the discernible social and cultural differences and to the 
differences in the administration of the self-efficacy assessments (verbal versus on paper) 
across the clinical sites outside the U.S., subjects at non-U.S. sites were not included in 
the present analysis.  This resulted in a sample of 1,447 patients for this analysis. 
Hispanic ethnicity was self-reported if the person was of Latin/Spanish culture or origin, 
regardless of race. Race was self-reported based on the U.S. Census Classification 
System as either 1) American Indian/Alaskan Native, 2) Asian, 3) Black/African 
American, 4) Native Hawaiian/Pacific Islander, 5) White, or 6) Other (including those of 
multiple races).  
 
 2.3 VARIABLES 
Self-efficacy is the key measurement of one’s self-confidence in medical self-
management. Thereby, it serves as the main psychological measure for this proposal.  At 
study entry, BARI 2D participants completed the SE questionnaire, as well as a 
comprehensive battery of psychosocial quality of life measures regarding their own 
health, self-rated health, energy, health distress, and ability to do different activities.  
Demographic information, clinical history, prescribed pharmaceuticals, and quality of life 
data were also collected.  
HbA1c is used as a measure of diabetic severity, while LDL and systolic blood 
pressure are used as measures of cardiovascular risk. One-minute resting blood pressure 
was measured with participants in the seated position. The systolic blood pressure and 
diastolic blood pressure reported are based on an average of the two sitting blood 
pressures. Hypertension is defined as a blood pressure level >140/90 mmHg 
(BARI_2D_Coordinating_Center, 2002-2005). Fasting total, low density lipid (LDL) 
cholesterol, and high density lipid (HDL) cholesterol, fibrinolytic factors, insulin, and 
HbA1c levels were measured from blood samples collected at baseline and were analyzed 
at the BARI 2D core Biochemistry Laboratory. LDL was calculated using the Friedwald 
equation (Friedwald & Frederickson, 1972). Urine specimens were assayed at the 
Biochemistry Laboratory for albumin and creatinine in order to diagnose micro- and 
macroalbuminuria. Medication adherence was not measured in BARI 2D, only the types 
of medication prescribed. Patients with a history of health problems may be clinically 
under control, because of the medications they are using. Therefore, the medications used 
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 could serve as a surrogate for a history of medical problems for which they are taken 
(e.g., high LDL or high blood pressure). 
2.3.1 Assessments 
2.3.1.1 Self-efficacy.  
The self-efficacy assessment of the quality of life section (Appendix A) attempts to 
measure how confident the patient is in his/her ability to do tasks and activities that relate 
to managing his/her DM and CAD in general and specific ways. The ambiguous term 
“management” may be interpreted as something as simple as trying to monitor glucose 
regularly or to a more complex regimen of a specific diet with regular exercise. Patients 
were encouraged to personally consider what tasks and activities they do on a day-to-day 
basis, in order to measure confidence in the ability to keep DM and CAD “under 
control.” 
The SE assessment used in BARI 2D is originally from the Chronic Disease Self-
Management Study (Lorig, 1996) and was found to have high internal consistency in that 
study (Crohnbach’s α=0.92). The sample used to test this instrument was mostly White 
non-Hispanic (nH; 91.1%) and female (68.0%), with a mean age of 64.4 years (Lorig, 
1996).  It should be noted that the original SE assessment has five items, however the 
BARI 2D assessment used only four (Crohnbach’s α=0.89).  The fifth question regarding 
the patient’s ability to visit a health care professional was omitted since the patients are 
closely monitored and managed within the BARI 2D clinical trial with a high level of 
professional care and oversight.  The questions have also been modified from disease 
management in general to address heart disease and DM specifically. Each question 
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 consists of a 10-point Likert scale with “1=not at all confident” and “10=totally 
confident.” Interest lies in the patients’ confidence in 1) doing all day-to-day things 
necessary to manage their conditions, 2) doing activities for their DM and CAD in order 
to reduce doctor visits, 3) reducing emotional stress associated with their diseases 
through acts such as prayer, meditation, art, and social contact, and 4) doing activities 
besides medication adherence, such as exercise, hobbies, and diet, to reduce the impact of 
the diseases on their daily life.  
2.3.1.2 Additional quality of life assessments. 
With self-rated health, patients are asked to rate their general health as either “Excellent,” 
“Very Good,” “Good,” “Fair,” or “Poor” (Ware & Sherbourne, 1992).  Health distress 
and energy are assessed by a 9-item questionnaire in which patients report how they have 
felt during the past four weeks (Stewart & Ware, 1992). Patients are read five answer 
options which range from “All of the Time” to “None of the Time.” The Duke Activity 
Status Index (DASI) is a 12-item questionnaire that measures the functionality of the 
patients in daily and recreational activities (Crohnbach’s α=0.67) (Dorian et al., 2002). 
2.3.2 Statistical Analyses 
The first step was to assess the normality of the distribution of the continuous baseline 
variables: SE score, HbA1c, LDL, and systolic blood pressure. For each of these 
variables, the hypothesis of normality was formally rejected (Kolmogorov-Smirnov 
p<0.01).  However, given the large sample size in this analysis (N=1,447), there was 
power to detect small departures from normality based on skewness, kurtosis, and visual 
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 inspection. The distributions of the SE score (mean=7.7, s.d.=1.8, skewness=-0.75, 
kurtosis=0.23), HbA1c (mean=7.67, s.d.=1.62, skewness=0.94, kurtosis=0.60), LDL 
(mean=96.8, s.d.=34.0, skewness=1.01, kurtosis=2.80) and systolic blood pressure 
(mean=131.7, s.d.=20.0, skewness=0.79, kurtosis=1.13) can be considered approximately 
normal (Figures 2 and 3). SE was used a continuous variable (0-10) in this analysis. 
Previous literature that investigated SE as a continuous measure did not transform the SE 
variable and used non-parametric statistics to account for the non-normal distributions. 
Lowess smoothed plots (bandwidth=0.2 and bandwidth=0.4) of the explanatory risk 
factor variables versus SE were examined, and it was determined from visual inspection 
that linear forms of the variables were appropriate for the current analyses. Therefore, the 
SE variable was not transformed. 
Cut-off points for clinical variables such as ankle brachial index and diastolic 
blood pressure were based on a review of literature for their clinical thresholds. The SE 
scores of baseline demographic and clinical categories were compared using chi-square 
statistics for categorical variables and Wilcoxon non-parametric statistics for continuous 
variables. Non-parametric statistics were used for between group comparisons of 
categorical variables (i.e., men vs. women, history of congestive heart failure vs. no 
congestive heart failure) for the SE score. The p-values were based on the Wilcoxon 
signed-rank test (2 groups) or the Kruskal-Wallis test (more than 2 groups). P-values for 
the group variables of race/ethnicity, albuminuria, and angina status are reported. 
Variables to be considered included demographics and clinical characteristics presented 
in Table 2. Based on the literature, candidate variables of interest for the analysis also 
included drug use, marital status, duration of DM, and ST segment depression. 
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 Regression models with the outcome of SE were constructed, both unadjusted and 
adjusted for age, race/ethnicity, education, and sex. Risk factors were stratified by 
race/ethnicity, sex, and education. Two-way ANOVAs were performed to test within 
category differences of the demographic variables and interactions between the 
independent variables. 
A multivariate model with the outcome of SE was created. First, a stepwise linear 
regression model (p<0.10) was created from the following domains in the following 
sequence: demographics – sex, age, race/ethnicity, education, marriage status, BMI; 
clinical history – HbA1c, duration of diabetes, current insulin use, history of 
hypoglycemia, albumin creatinine ratio >30, probable neuropathy as indicated by a 
Michigan Neuropathy Screening score ≥7 (Feldman et al., 1994), LDL ≥100, systolic 
blood pressure >130, diastolic blood pressure <70, history of congestive heart failure, 
non-coronary artery disease, angina status, total cholesterol ≥200, low HDL, ankle 
brachial index ≤0.90, ST segment depression >.5mm; and medications – number of 
hypertension drugs, number of lipid drugs, number of diabetes drugs, and no diabetes 
drugs. In order to create a parsimonious model of factors associated with SE, variables 
that entered the resulting model with a p≥0.05 were individually removed from the model 
until the final model contained only variables with p<0.05. All analyses were performed 
using SAS version 9.1.   
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Figure 2. Histograms of Self-efficacy score and HbA1c 
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Figure 3. Histograms of low density lipids and systolic blood pressure
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3.0  RESULTS 
3.1 BASELINE DEMOGRAPHICS AND CLINICAL HISTORY 
In the U.S. sites, 1,447 patients completed the SE questionnaire. The characteristics of these 
patients at study entry are shown in Table 2. Patients were predominately male (68.3%), with an 
average age of 62.8 years. The patients were racially and ethnically diverse, with 59.4% White 
non-Hispanics (nH), 22.9% Black nH, 14.2% Hispanic, and 3.5% Other (including Asian and 
Native American). Half of the patients had an education beyond high school, including associate 
degrees, bachelor degrees, and advanced degrees.  The mean body mass index (BMI) was 32.9 
kg/m2, which is considered obese.  
The average duration of diabetes in the BARI 2D patients was 10.9±8.9 years. Patients 
had a mean HbA1c of 7.6% ±1.6% and probable neuropathy was screened in 18.1% of patients.  
Few patients were not taking any diabetes drugs (6%) and about a third were taking insulin at the 
time of randomization. The mean SE score was 7.7±1.8. Most of the patients (39.8%) rated their 
health as “Good.” However, the patients rated their energy and their ability to carry out daily 
activities as low. 
A low percentage of patients had a history of congestive heart failure. A large proportion 
of the patients had a clinical history of hypertension and hypercholesterolemia requiring 
treatment. More than a quarter (27.9%) of the patients had non-coronary artery disease and 
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37.3% of patients reported angina status that was mild to moderate (Canadian Classification 
System [CCS] 1, 2) (Campeau, 1975). There were 2.6±1.9 lesions per patient on average. Few 
patients had major Q-wave MI. A quarter of the patients had high blood pressure, as indicated by 
a blood pressure >140/90 mmHg. The BARI 2D target blood pressure was 130/80. The mean 
systolic blood pressure was 130.7±19.0, the mean diastolic blood pressure was 72.5±10.4, and 
the mean LDL was 95.4±34.3 mg/dl. Patients were prescribed an average of 2.3±1.0 drugs for 
their hypertension.  
3.2 SELF-EFFICACY SCORE 
Table 3 presents the SE score mean and standard deviation (s.d.) for each category. Variables 
presented in the table were chosen if they were clinically significant or were shown to be related 
to SE from past literature. The SE score was significantly different between racial/ethnic groups 
with the White BARI 2D patients having the highest mean SE score and the Hispanic patients 
having the lowest. There was no significant difference between the age categories or by BMI. 
Males and those with higher education had significantly higher SE scores than females and those 
with less education.  Patients who exercised daily had significantly higher SE scores than 
patients who did not exercise daily. Patients with HbA1c <8% had significantly higher SE 
scores. Differences between SE scores by systolic blood pressure and LDL categories were not 
significant. 
Patients with a healthier diabetic profile -- no history of hypoglycemia, no neuropathy, no 
micro-albuminuria (30< albumin creatinine ratio [acr] <300) or macro-albuminuria (acr≥300),  
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 Patients with a healthier cardiac profile -- no additional history of treated congestive heart 
failure or hypertension, no angina or angina only with MI, no ST segment depression >.5 mm, an 
ankle brachial index >1.4, and fewer hypertension medications -- had significantly higher mean 
SE scores that those with a less healthy profile. However, patients who had a history of 
malignancy had higher SE scores than those without a history of malignancy. The SE scores 
between diastolic blood pressure categories were not significantly different. 
The SE scores by the three risk factors, HbA1c, systolic blood pressure, and LDL, were 
stratified by race/ethnicity, sex, and education. Figure 4 depicts the results from the two-way 
ANOVAs in graphical form. The SE difference between HbA1c categories shown in Table 3 
remained significant when stratified by race/ethnicity (p=0.02), sex (p=0.03), and education 
(p=0.01). The relationships between SE and systolic blood pressure and LDL remained non-
significant even after stratifying by these demographics. No risk factors met the p<0.05 
significance for interactions between risk factors and demographic variables. Therefore, the 
association between the risk factors and SE is the same regardless of the demographic status. 
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 Table 2. Demographic and clinical characteristics 
Characteristic 
Total 
(N=1,447) 
DEMOGRAPHICS  
Male, % 68.3 
Age at study entry (years), mean, s.d. 62.8, 9.1 
Race/Ethnicity, %  
  White non-Hispanic (nH) 59.4 
  Black nH 22.9 
  Hispanic 14.2 
  Other nH 3.5 
Education categories, %  
   < High school 23.8 
   High school graduate 26.5 
   Some post high school 30.0 
   Bachelor degree or higher 19.6 
Medicare/Public insurance, % 55.1 
BMI, mean, s.d. 32.9, 6.2 
RISK FACTORS OF INTEREST  
HbA1c %, mean, s.d. 7.60, 1.58 
Sitting systolic blood pressure average, mean, s.d. 130.7, 19.0 
Low density lipids mg/dl, mean, s.d. 95.4, 34.3 
DIABETES  
Duration of diabetes (years), mean, s.d. 10.9, 8.9 
Probable neuropathy (Michigan neuropathy screening score ≥7), % 18.1 
Albuminuria categories, %  
   No albuminuria 66.1 
   Micro albuminuria, 30<acr<300 23.4 
   Macro albuminuria, acr ≥300 10.5 
No diabetes drugs, % 6.6 
Currently taking insulin, % 33.4 
CARDIAC  
History of congestive heart failure requiring treatment, % 9.1 
Hypertension requiring treatment, % 84.2 
Hypercholesterolemia requiring treatment, % 83.7 
Non-coronary artery disease, % 27.9 
History of malignancy (cancer), % 10.6 
Angina category w/i 6 weeks, %  
  Angina Only with MI / No Angina nor Angina Equivalents 17.8 
  Anginal Equivalents 24.9 
  Stable CCS1, CCS2* 37.3 
  Stable CCS3, CCS4, Unstable 20.1 
Number of lesions with ≥ 50% stenosis, mean, s.d. 2.6, 1.9 
Proximal left anterior descending artery (LAD) ≥ 50% stenosis, % 12 
Major Q-wave myocardial infarction, % 6 
ST segment depression > 0.5 mm, % 14.2 
Sitting blood pressure >140/90, % 25.9 
Sitting diastolic blood pressure average, mean, s.d. 72.5, 10.4 
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 Table 2 (cont.)  
Characteristic 
Total 
(N=1,447) 
Total cholesterol mg/dl, mean, s.d. 167.1, 40.5 
Triglycerides, mean, s.d. 175.3, 135.0 
High density lipids mg/dl, mean, s.d. 38.2, 10.8 
Number of hypertension drugs, mean, s.d. 2.3, 1.0 
Beta blocker, % 72.8 
Calcium channel blockers combined, % 31.7 
Angiotensin converting enzyme (ACE) inhibitor, % 66.7 
Angiotensin receptor blocker (ARB), % 16 
Diuretic, % 44.5 
Nonsublingual nitrate, % 29.5 
Sublingual nitrate spray, % 27.3 
QUALITY OF LIFE   
Self efficacy score (0-10), mean, s.d. 7.7, 1.8 
Self rated health category, %  
  Poor 13.2 
  Fair 35.3 
  Good 39.8 
  Very good 10.3 
  Excellent 1.3 
Quality of life energy score (0-100), mean, s.d. 45.4, 21.8 
Health distress score (0-100), mean, s.d. 56.2, 25.3 
Quality of life Duke Activity Score Index (DASI) (0-58.2), mean, s.d. 18.7, 14.2 
 
*Canadian Classification System for angina 
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 Table 3. Mean and s.d. of SE score between variable categories 
Variable  Categories (Mean, s.d.) P-value 
DEMOGRAPHICS         
Sex Female 
(N=461) 
Male 
(N=995)       
  7.5, 1.9 7.8, 1.8         <.001 
Race White nH 
(N=866) 
Black nH 
(N=333) 
Hispanic 
(N=207) 
Other nH 
(N=50)     
  8.0, 1.7 7.6, 2.0 7.0, 2.0 7.5, 1.9     <.001 
Age  <50 yrs 
(N=113) 
50-59 yrs 
(N=457) 
60-69 yrs 
(N=533) 
≥ 70 yrs 
(N=353)     
  7.6, 1.9 7.6, 1.9 7.9, 1.8 7.7, 1.8     0.12 
Education Some HS/ 
Less   
(N=26) 
HS 
Diploma 
(N=385) 
Some post 
HS 
(N=434) 
Bachelors/ 
Higher 
(N=170)     
  6.3, 2.3 7.5, 1.9 8.0, 1.6 8.3, 1.5     <.001 
Marital status Never 
married 
(N=89) 
Married/ 
spouse-like 
(N=964) 
Divorced/ 
Separated 
(N=253) 
Widowed 
(N=150)     
  7.5, 2.1 7.8, 1.7 7.4, 2.0 7.7, 1.9     0.01 
Exercise daily No 
(N=1093) 
Yes 
(N=360)       
  7.6, 1.9 8.3, 1.5         <.001 
BMI  Low,  
<20  
(N=3) 
Normal,  
20-<25 
(N=104) 
Overwt.,  
25-<30 
(N=405) 
C1 Obese, 
30-<35 
(N=492) 
C2 Obese, 
35-<40 
(N=264) 
C3/4 
Obese, ≥40 
(N=177)   
  8.0, 1.0 7.5, 2.1 7.8, 1.8 7.8, 1.8 7.7, 1.7 7.5, 2.0 0.17 
RISK FACTORS OF INTEREST    
HbA1c  <7 
 (N=564) 
7-<8 
(N=364) 
≥ 8 
(N=516)      
  7.8, 1.7 7.9, 1.8 7.5, 2.0       0.01 
Systolic blood pressure  
<130 
(N=740) 
(130-140) 
(N=315) 
≥140 
(N=392)      
 7.8, 1.8 7.7, 1.7 7.6, 1.9      0.40 
LDL  
<100 
(N=876) 
100-<130 
(N=355) 
≥130 
(N=194) 
 
   
 7.8, 1.9 7.7, 1.8 7.6, 1.9    0.36 
DIABETIC FACTORS        
History of 
hypoglycemia 
No 
(N=1038) 
Yes 
(N=401)       
  7.8, 1.8 7.6, 1.7         0.04 
Probable neuropathy No 
(N=1188) 
Yes 
(N=262)       
  7.9, 1.8 7.1, 2.0         <.001 
Albuminuria  No 
albuminuria 
(N=864) 
Micro 
albuminuria 
(N=307) 
Macro 
albuminuria 
(N=136)      
  7.8, 1.8 7.6, 1.8 7.4, 2.0       0.02 
Diabetes drugs 
None 
(N=97) 
1, no 
insulin 
(N=398) 
≥2, no 
insulin 
(N=476) 
Insulin 
(N=485)     
 8.2, 1.6 7.9, 1.8 7.8, 1.7 7.4, 1.9   <.001 
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 Table 3 (cont.)        
Variable  Categories (Mean, s.d.) P-value 
CARDIAC FACTORS        
History of congestive 
heart failure 
No 
(N=1315) 
Yes 
(N=132)       
  7.8, 1.8 7.0, 2.0         <.001 
History of hypertension No 
(N=227) 
Yes 
(N=1222)       
  8.1, 1.6 7.7, 1.9         <.001 
Non-coronary artery 
disease 
No 
(N=1048) 
Yes 
(N=408)       
  7.8, 1.8 7.4, 1.9         <.001 
History of Malignancy 
(cancer) 
No 
(N=1300) 
Yes 
(N=156)       
  7.7, 1.9 8.1, 1.6         <.001 
Angina status* Only w/ 
MI/Neither 
(N=257) 
Angina 
Equivalent 
(N=361) 
Angina 1, 2 
(N=548) 
Angina 3, 4 
(N=290)     
  8.1, 1.8 7.8, 1.7 7.7, 1.9 7.4, 1.9     <.001 
ST segment depression 
>.5mm 
No 
(N=1122) 
Yes 
(N=185)       
  7.8, 1.8 7.5, 1.9        0.03 
Diastolic blood 
pressure  
<70 
(N=577) 
70-<80 
(N=519) 
≥80 
(N=350)      
  7.6, 1.9 7.7, 1.8  7.7, 1.8       0.18 
Ankle brachial index ≤ 0.90 
(N=258) 
 >0.90-1.4 
(N=980) 
>1.4 
(N=36)      
  7.4, 1.8 7.8, 1.8 8.4, 1.2       <.001 
Number of 
hypertension drugs 0 (N=56) 1 (N=226) 2 (N=562) 3 (N=435) 4 (N=164) 5 (N=13)   
  8.3, 1.6 8.1, 1.7 7.8, 1.8 7.6, 1.9 7.4, 2.0 7.3, 2.2 <.001 
 
Key: SE – self efficacy, BMI- body mass index, HS – high school, nH – non-Hispanic, C1–C4: Class 1 – 4 obesity, 
HbA1c – glycosylated hemoglobin, LDL – low density lipid cholesterol, MI – myocardial infarction 
  
*Canadian Classification System for angina 
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Figure 4. Mean SE Scores for risk factors by race/ethnicity, sex, and education 
Key: SE – self efficacy, HbA1c – glycosylated hemoglobin, SBP – systolic blood pressure, LDL – low  
density lipid cholesterol, HS – high school, nH – non-Hispanic 
No values met the p<0.05 significance for interactions between risk factors and demographics for SE 
based on two-way ANOVAs. 
P-values presented represent the difference in SE scores between HbA1c categories. 
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3.3 BIVARIATE AND MULTIVARIATE MODELS 
Table 4 shows the bivariate and multivariate regression models for SE. Model 1 is unadjusted 
and Model 2 is adjusted for sex, age, race/ethnicity, and education. In Model 1, female, Black 
and Latino race/ethnicity, and a post high school education (high school diploma and above) 
were significantly associated with SE. Age and Other race/ethnicity were not significantly 
associated with SE. Race/ethnicity was related to SE (p<.001), and minority racial/ethnic groups 
compared to White patients had lower SE scores. Compared to White patients, Black patients 
scored 0.34 lower, Hispanics scored 1.02 lower, and Other racial/ethnic patients scored 0.52 
lower (non-significant) on the SE score. A post high school education was positively associated 
with SE. Regular exercise and being married were both positively associated with SE. 
 HbA1c, defined both continuously and dichotomously (≥8%), was significantly 
negatively associated with SE score, as was systolic blood pressure per 10 mmHg. LDL, 
continuously and dichotomously (≥100), was not significantly associated with SE. 
Diabetic factors that were negatively associated with SE were duration of diabetes per 5 
years, history of hypoglycemia, probable neuropathy, albuminuria, and current insulin use. 
Patients who were not on diabetes drugs had significantly higher SE scores than patients on 
diabetes drugs.  
Cardiac factors that were negatively associated with SE were a history of congestive 
heart failure, hypertension, ankle brachial index ≤.90, non-coronary artery disease, angina CCS 
3, 4 or unstable angina, ST segment depression, and number of hypertension drugs. Surprisingly, 
a history of malignancy (cancer) at baseline was positively associated with SE.  Diastolic blood  
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 pressure <70, low HDL, total cholesterol, and number of lipid drugs were not significantly 
related to SE.  
In Model 2, sex, age, race/ethnicity, and education serve as the reference model. Each 
demographic variable is adjusted for the other demographic variables. For example, age is 
adjusted for sex, race/ethnicity, and post high school education. Latino, Other race/ethnicity, and 
a post high school education were significantly associated with SE. The Black nH, female, and 
age variables were not significantly associated with SE.  BMI was not significantly associated 
with SE, but regular exercise and being married were significantly related to a higher SE score. 
HbA1c was the only risk factor of interest that was significantly negatively associated with SE 
score.   
Additional diabetic factors that were negatively associated with SE were duration of 
diabetes per 5 years, history of hypoglycemia, probable neuropathy, albuminuria, current insulin 
use, and no use of diabetes drugs. Cardiac factors that were negatively associated with SE were a 
history of congestive heart failure, hypertension, ankle brachial index ≤.90, non-coronary artery 
disease, no diagnosis of malignancy, angina status, ST segment depression, and number of 
hypertension drugs. Low HDL, total cholesterol, and number of lipid drugs were not 
significantly related to SE after adjusting for confounders. Diastolic blood pressure <70, which 
showed no significant association in the unadjusted bivariate model, was significantly negatively 
associated with SE in the adjusted model. 
 A multivariate linear regression model was also created to examine the contribution of 
baseline risk factors in determining the level of SE (Table 5). This analysis is different from that 
in Table 4 in that it looks at a variable’s association with SE controlling for sex, age, 
race/ethnicity, post high school education, and additional clinical variables. Variables that 
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 entered the model were probable neuropathy, current insulin use, history of congestive heart 
failure, number of hypertension drugs, and a history of cancer.  Probable neuropathy, current 
insulin use, a history of treated congestive heart failure, and hypertension drugs were 
significantly associated with a decrease in SE. A history of cancer was associated with an 
increase in SE. This model explains 12% of the variance in the SE score as indicated by the 
adjusted R2. 
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 Table 4. Unadjusted bivariate and adjusted models: outcome SE score (0-10) 
  Model 1: Unadjusted Model 2: Adjusted* 
Variable Coefficient P-value Coefficient P-value 
DEMOGRAPHICS   reference model in italics 
Female -0.33 <.001 -0.20 0.06 
Age (per 5 years) 0.05 0.06 0.05 0.06 
Black nH (vs. White nH) ** -0.34 <.001 -0.16 0.19 
Hispanic or Latino  (vs. White nH) ** -1.02 <.001 -0.80 <.001 
Other  nH (vs. White nH) ** -0.52 0.05 -0.53 0.04 
Post HS education and above (vs. ≤HS education) 0.78 <.001 0.68 <.001 
BMI (per 5 points) -0.05 0.18 -0.06 0.14 
Exercise regularly 0.74 <.001 0.59 <.001 
Married                                               0.34 <.001 0.26 0.01 
RISK FACTORS     
HbA1c % -0.10 <.001 -0.07 0.02 
HbA1c ≥ 8.0% -0.30 <.001 -0.22 0.03 
Sitting systolic blood pressure (per 10 mmHg) -0.06 0.03 -0.01 0.06 
Sitting systolic blood pressure >140 -0.16 0.14 -0.13 0.22 
LDL per 10 mm/dl -0.02 0.46 -0.01 0.68 
LDL ≥ 100 -0.10 0.35 0.01 0.91 
DIABETIC     
Duration of diabetes (per 5 years) -0.06 0.03 -0.05 0.04 
History of hypoglycemic episode -0.22 0.04 -0.23 0.02 
Probable neuropathy -0.79 <.001 -0.66 <.001 
Micro albuminuria 30<acr ≤300 mg/g (vs. none) -0.20 -0.19 
Macro albuminuria acr>300 mg/g (vs. none) -0.44 }       0.02 -0.37 }        0.04 
Currently taking insulin -0.51 <.001 -0.47 <.001 
No diabetes drugs 0.46 0.02 0.39 0.04 
CARDIAC     
History of congestive heart failure requiring 
treatment -0.77 <.001 -0.72 <.001 
Hypertension requiring treatment -0.48 <.001 -0.40 0.00 
Ankle brachial index ≤.90 -0.27 0.01 -0.21 0.04 
Non-coronary artery disease -0.41 <.001 -0.37 0.00 
History of malignancy (cancer) 0.42 0.01 0.37 0.02 
Angina equivalent (vs. no angina) -0.26 -0.19 
Angina CCS 1, 2 (vs. no angina) -0.42 -0.30 
Angina CCS 3, 4, Unstable (vs. no angina) -0.65 }   <.001 -0.48 }    0.02 
ST segment depression >.05mm -0.31 0.03 -0.36 0.01 
Diastolic blood pressure <70 -0.14 0.15 -40.23 0.02 
HDL < 40 males, < 50 mg/dl females -0.01 0.96 -0.03 0.76 
Total cholesterol ≥ 200 mg/dl -0.19 0.15 -0.09 0.50 
Number of hypertension drugs -0.23 <.001 -0.24 <.001 
Number of lipid drugs -0.10 0.20 -0.16 0.05 
 
Key: SE – self-efficacy, nH – non-Hispanic, BMI – body mass index, HbA1c – glycosylated hemoglobin, LDL – 
low density lipids, acr – albumin creatinine ratio, CCS 1-4 – Canadian Classification System, HDL – high 
density lipids 
*   Sex, age, race/ethnicity, and post high school education serve as the reference model for which the latter 
variables are adjusted. 
**   Test for significance of race/ethnicity unadjusted p<.001, adjusted p<.001 
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 Table 5. Multivariate linear regression model- SE score (0-10) 
Variable Coefficient P-value 
Intercept* 7.71 <.001 
Female -0.09 0.37 
Age (per 5 years) 0.04 0.12 
Black nH (vs. White nH) -0.04 0.75 
Hispanic or Latino (vs. White nH) -0.74 <.001 
Other nH (vs. White nH) -0.46 0.07 
Post HS education and above (vs. ≤HS education) 0.67 <.001 
Probable neuropathy -0.46 <.001 
Currently taking insulin -0.33 <.001 
History of congestive heart failure requiring treatment -0.50 <.001 
Number of hypertension drugs -0.20 <.001 
History of malignancy (cancer) 0.36 0.02 
Adjusted R2=0.12   
 
Key: nH – non-Hispanic, HS – high school 
*     Sex, age, race/ethnicity, and education were forced into the model.
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 4.0  DISCUSSION 
Type 2 diabetes and coronary artery disease continue to be growing problems in the U.S., and the 
control of the diseases’ risk factors is not simply a measure of prescribed healthcare regimens as 
given by one’s physician (Jerant et al., 2005). Psychosocial factors play a considerable role in the 
management of these comorbid diseases. In this analysis of BARI 2D patients with both Type 2 
diabetes and known CAD, self-efficacy was independently and positively associated with better 
profile for cardiac and diabetic risk factors and measures. Better HbA1c was positively 
associated with SE, which is consistent with the past literature that looked at DM both separately 
and in conjunction with CAD (Deaton et al., 2006; Nakahara et al., 2006). HbA1c was 
significantly associated with SE, even after adjusting for sex, age, race/ethnicity, and education. 
Consistent with the results of the study by Senuzun et al. (1996), systolic blood pressure was 
associated with SE when there was no adjustment for clinical and demographic confounders. 
However, in the current analysis, this association was not significant when adjusting for 
demographic confounders only. LDL was not associated with SE, which is counter to the results 
by Senuzun et al. (1996), which showed LDL to be significantly improved in a group of patients 
who received SE-improving skills compared to a control group. The relationship between SE and 
the risk factors did not differ by race/ethnicity, sex, and education. 
The clinical and demographic factors that were examined in BARI 2D account for an 
important proportion of one’s SE. Like the study by Deaton et al. (2006), the multivariate model 
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 in this analysis accounted for 12% of the variance of the SE score. This suggests that one’s 
clinical status is not the sole component in SE regarding one’s health. 
Education and literacy are important factors in SE. In this analysis, BARI 2D Hispanic 
patients were more likely than non-Hispanic patients to have lower SE. This may be a reflection 
of cultural differences or a matter of English literacy. Limited English skills can impair one’s 
health literacy. Poor literacy has been associated with worse DM outcomes and poor SE has been 
found to be negatively associated with self-management across race/ethnicity and health literacy 
levels (Kim, Love, Quistberg, & Shea, 2004; Sarkar et al., 2006). Furthermore, less educated 
BARI 2D patients had significantly lower SE, emphasizing the role that health education and 
literacy have on a patient’s confidence to effectively manage their chronic conditions. The SE 
assessment in BARI 2D was designed to be self-reported. Patients had to read a list of questions 
regarding their ability to manage their conditions. In the case that a person indicated that they 
were not able to read the questions, the assessment was administered by a BARI 2D staff 
member.  
In this analysis, probable neuropathy and insulin use were diabetic factors strongly 
associated with SE, both unadjusted and adjusted for confounders. The impact of neuropathy on 
quality of life has been well documented (Argoff, Cole, Fishbain, & Irving, 2006; Barrett et al., 
2007). Neuropathy is a clinical complication in which there is numbness, tingling, and/or pain in 
the body’s extremities, such as the hands and feet. The painful symptoms have been found to 
significantly diminish one’s quality of life. In a meta-analysis by Argoff et al. (2006), diabetic 
neuropathy was associated with the impairment of emotions, enjoyment of life, energy, pain, 
physical mobility, employment, and recreational and social activities. These impairments can 
affect the daily regimens needed to properly manage the chronic diseases. Insulin use is 
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 indicative of more severe diabetes and is also a more complex regimen requiring intense 
management. Current insulin use was independently and negatively associated with SE, even 
after controlling for confounding demographic variables. Compared to patients with no current 
use of insulin, patients who were currently using insulin rated their estimated SE score close to a 
half-point lower.  
The cardiac factors mainly associated with SE were history of congestive heart failure 
and use of hypertension drugs. Self-efficacy expectations are shaped by successful and failed 
outcomes (Bandura, 1977), and therefore, congestive heart failure can impair a persons’ belief 
that they are able to effectively mange their CAD. Congestive heart failure can be seen as the 
negative outcome of a failed attempt to manage one’s disease, thereby lowering one’s SE in 
prospective self-management. In other words, because congestive heart failure is seen as 
“failure,” the person then believes that s/he is no longer able to effectively manage his/her 
disease. Also, low SE can result in poor cardiac health management, which results in congestive 
heart failure. The symptoms of congestive heart failure can be very painful, and the level of pain 
may serve as a measure of how well or poorly a patient is taking care of his/herself. The 
association between SE and the number of hypertension drugs indicates that the management of 
the disease affects SE, and not the disease per se. Hypertension is commonly known as the 
“silent killer” because it has no immediate painful symptoms. However, the use of hypertension 
drugs serves as a reminder to the patient that they are indeed suffering from a potentially deadly 
condition, and number of drugs taken is representative of the magnitude of this condition. 
Similar to the results by Sullivan et al. (1998), ST segment depression was also negatively 
associated with SE. 
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 A history of malignancy was found to be positively associated with SE. This relationship 
may be indicative of a form of empowerment. If a patient feels they can survive cancer, then 
their positive outlook on life, as well as self-efficacy for health management behaviors, increases 
(Andrykowski, Beacham, Schmidt, & Harper, 2006; Park & Gaffey, 2007). DM and CAD may 
seem manageable in comparison. Furthermore, these patients’ bodies may have been relatively 
physically fit, enabling them to survive cancer. 
The main strengths of this analysis are the large sample size and the extent of clinical, 
demographic, and pharmaceutical data collected on each patient. This study adds to the sparse 
amount of literature that investigates SE in patients with two conditions that are highly 
comorbid. This sample is racially and ethnically diverse. BARI 2D surpassed its goal of 
recruiting 30% of the study participants from minority populations. In this analysis, over 40% of 
the U.S. patients were self-identified as racial/ethnic minorities. Furthermore, this study also 
collected data on history of malignancy, which was found to be significantly associated with SE. 
No other studies in the examined literature looked at cancer’s relationship to SE in patients with 
CAD and/or DM. Another strength of the study is that the longitudinal design will allow future 
analyses to further explore the temporal relationship between SE, DM and CAD control, clinical 
outcomes, and risk factors at multiple time points. The level of SE can be seen over time in 
relation to clinical measures. 
There are several limitations to this analysis. First, these analyses are cross-sectional so 
causation and directionality cannot be established. It is unclear whether or not a controlled 
medical profile is the successful result of high SE or if high SE is attained through the successful 
management of less severe disease. Second, SE is not constant over time. It can increase or 
decrease based on the failures and successes in goal attainment (Gist & Mitchell, 1992). BARI 
 43 
 2D is a longitudinal study so this analysis sets the starting point for an in-depth longitudinal 
analysis of SE over time. Third, the BARI 2D patient population is a select one (see 
inclusion/exclusion criteria for this clinical trial); therefore, the results of this analysis may not 
be generalizable to patients with DM or CAD only.  
An additional limitation is that the baseline data of BARI 2D do not contain an 
assessment of depression, another condition that is highly comorbid with DM and CAD 
(Ciechanowski et al., 2000; Katon et al., 2004). Follow-up BARI 2D data collection includes the 
Center for Epidemiological Studies Depression Scale (CES-D), an epidemiological measurement 
of the severity of depression symptoms (Radloff, 1977). This will provide an opportunity to look 
not only at the role depression plays in SE, but in clinical risk factors as well.  
It is of note that SE is specific based on the behavior in question; it is not a generalized 
response or a trait (Clark & Dodge, 1999). An additional point to keep in mind is that this is a 
modified SE assessment which contains four out of the five questions from the original 
assessment by Lorig (1996). The questions in the modified version of the SE assessment mention 
both diabetes and cardiovascular disease (Appendix A). This may be confusing to patients who 
are able to manage one disease properly, but not the other. For instance, a patient whose HbA1c 
is under control, but has high blood pressure may have difficulty answering question 4.2 
(Appendix A). The dual nature of these questions may cloud the independent effects of the 
comorbid diseases on SE.  
The results of this analysis have several implications. Clinical measures account for a 
proportion of what affects self-efficacy, and additional research can be done to describe 
additional influential factors such as family situations, living conditions, and additional chronic 
diseases. Health care providers should strongly take into consideration the patient’s clinical 
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 history and SE when assessing the patient’s ability to follow the prescribed healthcare regimens. 
Patient-provider communication must further emphasize building up the patient’s confidence, 
especially addressing physical pain and medication schedules. As indicated by the Bandura 
model, measures of past successes and failures in diabetes and cardiac control can affect one’s 
SE.  Diabetes educators should have the patients recognize their past management of DM and 
CAD collectively, and let patients know that a poor outcome should not negatively shape their 
outcome expectations. This can be done through counseling and examining what may have gone 
wrong in the past and how it can be changed in the future. Furthermore, culturally appropriate 
and comprehensible healthcare materials should be widely and readily available to those who 
may not fully understand English or have low literacy levels. Access to comprehensible 
healthcare information may lessen the disparities in the health profiles between people with 
different levels of literacy, education, and English. 
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 APPENDIX A 
SELF EFFICACY ASSESSMENT *  
(Adapted from Lorig, 1996) 
SECTION E: QUALITY OF LIFE 
4. We would like to know how confident you are in doing certain activities. For each of the following questions, 
please circle the number that corresponds to your confidence that you can do these things regularly at the present 
time. 
 
4.1 Having diabetes and heart disease often means doing different tasks and activities to manage your 
condition. How confident are you that you can do all the things necessary to manage your condition on a 
regular basis? 
 
Not at all     Totally 
Confident     1     2     3     4    5     6     7     8     9     10 Confident 
 
How confident are you that you can… 
4.2 Do the different tasks and activities needed to manage your diabetes and heart disease so as to reduce 
your need to see a doctor? 
 
Not at all     Totally 
Confident     1     2     3     4    5     6     7     8     9     10 Confident 
  
4.3 Reduce the emotional distress caused by your diabetes and heart disease so that it does not affect your 
everyday life? 
 
Not at all     Totally 
Confident     1     2     3     4    5     6     7     8     9     10 Confident 
  
4.4 Do things other than just taking medication to reduce how much your diabetes and heart disease affect 
your everyday life? 
 
Not at all     Totally 
Confident     1     2     3     4    5     6     7     8     9     10 Confident 
 
• Reprinted from BARI 2D Data Forms Manual, (BARI_2D_Coordinating_Center, 2002-
2004). 
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 APPENDIX B 
GLOSSARY OF ABBREVIATIONS 
The following terms are listed alphabetically: 
acr – albumin creatinine ratio 
BARI 2D – Bypass Angioplasty 
Revascularization Investigation 2 Diabetes 
BMI – body mass index 
C1, C2, C3, C4 – Class 1, Class 2, Class 3, 
Class 4 obesity 
CCS – Canadian Classification System 
DASI - Duke Activity Status Index  
DM – Type 2 diabetes mellitus 
HbA1c – glycosylated hemoglobin A1c 
HBCEP - home-based cardiac exercise 
program  
HDL – high density lipids 
HS – high school 
LDL – low density lipids 
MI – myocardial infarction 
nH – non-Hispanic 
n.s. – non-significant 
QoL – quality of life 
RX – drug prescriptions 
SBP – systolic blood pressure 
s.d. – standard deviation 
SE – self-efficacy 
SF-36 - Medical Outcomes Study 36-Item 
Short Form 
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